Kistarcsai Flor Ferenc Korhaz
- Address
- lock Available on a paid plan
Kistarcsai Flor Ferenc Korhaz - Multispecialty Clinical Research Center
Kistarcsai Flor Ferenc Korhaz is a comprehensive clinical research institution with extensive experience in immunological, rheumatological, neurological, and cardiovascular therapeutic areas. The center demonstrates particular expertise in conducting complex Phase III trials evaluating novel biologics and targeted therapies for autoimmune and inflammatory conditions.
- Rheumatological and musculoskeletal disorders including psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, and osteoarthritis
- Neurological conditions with focus on multiple sclerosis variants (relapsing MS, primary progressive MS) and myasthenia gravis
- Cardiovascular and metabolic diseases including thromboembolism, atherosclerotic cardiovascular disease, heart failure, and obesity-related complications
The center's research portfolio spans innovative monoclonal antibody therapies, JAK inhibitors, BTK inhibitors, and emerging treatment modalities including antisense oligonucleotides and Factor XIa inhibitors. With participation in comparative effectiveness studies, long-term extension trials, and pivotal registration studies, the institution contributes significantly to advancing treatment options for complex autoimmune diseases, chronic kidney disease, and cancer-associated thrombosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 93 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 92 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Immunovant Sciences GmbH2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kistarcsai Flor Ferenc Korhaz
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 93 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 3 | Unknown | 2022-08-10 | 2023-10-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.